Immunology News and Research

Latest Immunology News and Research

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

People infected with West Nile virus may have persistent virus in their kidneys, shows study

A new study shows that people who have been infected with West Nile virus may have persistent virus in their kidneys for years after initial infection, potentially leading to kidney problems.

8 Dec 2009

New bone marrow transplantation technique shows prompt immune recovery

Although bone marrow transplants have long been standard for acute leukemia, current treatments still rely on exact matches between donor and patient. Now, scientists at the University of Perugia, Italy, and the Weizmann Institute of Science have improved on a method of transplanting bone marrow-based stem cells from a mismatched donor, making it safer for use when no exact match exists.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

UCB presents data on Vimpat AED at AES meeting

UCB today announced new findings on its antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting the use of this AED as adjunctive therapy in adult patients with partial-onset seizures. Results of presented research demonstrate sustained efficacy in adult patients taking Vimpat® for up to three years, and a consistent long-term tolerability profile.

7 Dec 2009

Synexus to complete acquisition of ClinPharm by January 2010

Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to 26 in nine countries, thus significantly strengthening its European reach and further reinforcing its position as the global leader.

From AES - Accelerated Enrollment Solutions 7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

Researchers discover new strategy against invasive parasite

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a possible strategy against an invasive parasite that infects more than a quarter of the world's population, including 50 million Americans.

4 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

With flu season in full swing and the threat of H1N1 looming, demand for vaccines is at an all-time high. Although those vaccines are expected to be effective, University of Missouri researchers have found further evidence that some over-the-counter drugs, such as aspirin and Tylenol, that inhibit certain enzymes could impact the effectiveness of vaccines.

1 Dec 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

The DFG has approved the establishment of 17 new Collaborative Research Centres as of 1 January 2010. This decision was made recently by the relevant Grants Committee in Bonn.

1 Dec 2009

NRR to be available exclusively on OvidSP online search and discovery platform to all Ovid customers

As part of ongoing efforts to strengthen its presence in China's healthcare information market, Ovid, a part of Wolters Kluwer Health and a global leader in electronic scientific, medical, and academic information research solutions, is pleased to announce an agreement with Neural Regeneration Research (NRR), an English-language monthly journal dedicated to presenting peer-reviewed, evidence-based scholarly research in stem cells and regeneration.

1 Dec 2009

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Intelliject, Inc. today announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. shall be responsible for manufacturing and commercialization.

1 Dec 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

30 Nov 2009

Immunology News and Research

Latest Immunology News and Research

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

People infected with West Nile virus may have persistent virus in their kidneys, shows study

New bone marrow transplantation technique shows prompt immune recovery

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

UCB presents data on Vimpat AED at AES meeting

Synexus to complete acquisition of ClinPharm by January 2010

New approach to protein misfolding may lead to novel therapies for a number of diseases

GIND scientists identify drug treatments that can normalize neuron development in AD

Researchers discover new strategy against invasive parasite

Bioactive sponge to eliminate normally fatal tumors

New approach to identify molecules that prevent immune cells from attacking body

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

NRR to be available exclusively on OvidSP online search and discovery platform to all Ovid customers

Intelliject announces an exclusive license with sanofi-aventis for epinephrine auto-injector

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation